Granahan Investment Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Granahan Investment Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-355,360	Closed	-$4.08M	–	197
2023 Q3	$4.08M	Buy	355,360 +66,433	+23%	+$1.28M	0.15%	137
2023 Q2	$7.31M	Buy	288,927 +45,465	+19%	+$1.42M	0.23%	108
2023 Q1	$7.84M	Sell	243,462 -104,602	-30%	-$3.26M	0.24%	101
2022 Q4	$6.43M	Buy	348,064 +103,147	+42%	+$2.36M	0.2%	114
2022 Q3	$6.61M	Buy	244,917 +21,286	+10%	+$432K	0.22%	115
2022 Q2	$3.09M	Buy	223,631 +61,936	+38%	+$954K	0.11%	145
2022 Q1	$3.15M	Sell	161,695 -54,802	-25%	-$831K	0.08%	154
2021 Q4	$3.53M	Buy	216,497 +88,258	+69%	+$1.47M	0.07%	165
2021 Q3	$3.57M	Buy	+128,239	New	+$3.66M	0.07%	168

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Granahan Investment Management's RVNC Position: Q4 2023 in Review

Granahan Investment Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2023, closing a stake of 355,360 shares — an estimated $4.08M sold.

Granahan Investment Management first reported a position in RVNC in Q3 2021 and held it in 9 quarters. The position peaked at $7.84M in Q1 2023. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2023.

Granahan Investment Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
Granahan Investment Management sold 355,360 Revance Therapeutics, Inc. shares in Q4 2023, an estimated $4.08M.
Granahan Investment Management first reported a position in Revance Therapeutics, Inc. in Q3 2021 and held it in 9 quarters.
Granahan Investment Management's Revance Therapeutics, Inc. position peaked at $7.84M in Q1 2023.
193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2023.

Based on Granahan Investment Management's 13F filing for Q4 2023, filed 14 Feb 2024.